Takeda’s pivotal Phase II/III clinical trial of its investigational TAK-881K SCIG 20% with recombinant human hyaluronidase) in patients with primary immunodeficiency met its primary and secondary endpoints.
The U.S. Food and Drug Administration has approved ADMA Biologics’ supplemental biologics license application to expand the prescribing information to primary humoral immunodeficiency indication to pediatric patients 2 years of age and older.
U.S. Representatives Adrian Smith (R-NE-03) and Doris Matsui (D-CA-07) have introduced the PI Post Acute Access Act to expand access to lifesaving care for individuals with primary immunodeficiencies
Intravenous immune globulin (IVIG) improved clinical response rates in patients with autoimmune encephalitis (AE) who had inadequate response to steroid pulse therapy.
Wei Gao, PhD, assistant professor of pharmacology at the University of Houston College of Pharmacy, has received a $900,000 grant from the Cancer Prevention and Research Institute of Texas to develop a stronger and more targeted anti-tumor therapy for pancreatic and lung cancer.
The U.S. Health and Human Services (HHS) has developed a comprehensive plan to strengthen prevention, expand treatment and carry out the the Great American Recovery.
The Centers for Disease Control and Prevention (CDC) has awarded an unsolicited $1.6 million grant for vaccine research to Danish researchers whose studies have been challenged by mainstream scientists but championed by anti-vaccine activists
Trethera Corp. has been awarded a new $2.7 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).
The antibody CR9114 shows promise in combating future flu pandemics as it appears to neutralize any influenza virus.
The U.S. Food and Drug Administration has approved KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for KEYTRUDA (pembrolizumab).
GC Biopharma has developed a proprietary enzyme-linked immunoassay (ELISA) that effectively mitigates heterophilic antibody interference to precisely measure factor XI (FXI) levels.
A potentially effective mucosal vaccine platform has been developed to encourage broad, protective immunity against multiple influenza virus infections.